# Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma

> **NCT03514381** · PHASE4 · COMPLETED · sponsor: **Institut Claudius Regaud** · enrollment: 59 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Patients starting a treatment with Doxorubicin and Ifosfamide

## Key facts

- **NCT ID:** NCT03514381
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-18
- **Primary completion:** 2020-11-23
- **Final completion:** 2020-11-23
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03514381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03514381, "Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03514381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*